Eledon Pharmaceuticals, Inc.
ELDN
$2.72
-$0.06-2.16%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 85.28% | 68.95% | 85.04% | 25.34% | -45.59% |
| Total Depreciation and Amortization | -6.38% | -29.41% | -27.61% | -23.39% | -24.19% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -144.83% | -124.60% | -123.21% | -36.44% | 69.29% |
| Change in Net Operating Assets | 266.18% | 277.14% | 272.15% | -138.28% | -274.03% |
| Cash from Operations | -42.37% | -19.59% | 6.17% | -17.71% | -27.00% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -114.64% | -55.26% | 76.78% | 17.31% | -- |
| Cash from Investing | -114.64% | -55.26% | 76.78% | 17.31% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 304.74% | 304.40% | 61.60% | 45.60% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 304.74% | 304.40% | 61.60% | 45.60% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 106.96% | 130.77% | 104.96% | 49.49% | -35.23% |